{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:10:18Z","timestamp":1775848218148,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFC2300300"],"award-info":[{"award-number":["2021YFC2300300"]}]},{"name":"National Key Research and Development Program of China","award":["2022ZFJH03"],"award-info":[{"award-number":["2022ZFJH03"]}]},{"name":"National Key Research and Development Program of China","award":["2021C03068"],"award-info":[{"award-number":["2021C03068"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2021YFC2300300"],"award-info":[{"award-number":["2021YFC2300300"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2022ZFJH03"],"award-info":[{"award-number":["2022ZFJH03"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2021C03068"],"award-info":[{"award-number":["2021C03068"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Program of Zhejiang Province","award":["2021YFC2300300"],"award-info":[{"award-number":["2021YFC2300300"]}]},{"name":"Key Research and Development Program of Zhejiang Province","award":["2022ZFJH03"],"award-info":[{"award-number":["2022ZFJH03"]}]},{"name":"Key Research and Development Program of Zhejiang Province","award":["2021C03068"],"award-info":[{"award-number":["2021C03068"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Bloodstream infections by bacteria, especially multidrug-resistant bacteria, remain a worldwide public health concern. We evaluated the antibacterial activity of ceftobiprole and comparable drugs against different bloodstream isolates and different sequence types of methicillin-resistant Staphylococcus\u00a0aureus (MRSA) in China. We found that MRSA, methicillin-susceptible Staphylococcus aureus (MSSA), and methicillin-susceptible coagulase-negative Staphylococcus (MSCNS) displayed ceftobiprole sensitivity rates of &gt;95%, which are similar to the rates for linezolid, daptomycin, and vancomycin. Of the tested MRCNS strains, 90.4% were sensitive to ceftobiprole. The sensitivities of ST59, ST398, and ST22 MRSA to ceftobiprole were higher than that of ST239. Ceftobiprole\u2019s MIC50\/90 value against Enterococcus faecalis was 0.25\/2 mg\/L, whereas Enterococcus faecium was completely resistant to this drug. Ceftobiprole exhibited no activity against ESBL-positive Enterobacterales, with resistance rates between 78.6% and 100%. For ESBL-negative Enterobacterales, excluding Klebsiella oxytoca, the sensitivity to ceftobiprole was comparable to that of ceftazidime, ceftriaxone, and cefepime. The MIC50\/90 value of ceftobiprole against Pseudomonas aeruginosa was 2\/16 mg\/L, and for Acinetobacter baumannii, it was 32\/&gt;32 mg\/L. Thus, ceftobiprole shows excellent antimicrobial activity against ESBL-negative Enterobacterales and Pseudomonas aeruginosa (comparable to that of ceftazidime, ceftriaxone, and cefepime); however, it is not effective against ESBL-positive Enterobacterales and Acinetobacter baumannii. These results provide important information to clinicians.<\/jats:p>","DOI":"10.3390\/antibiotics13020165","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T11:03:14Z","timestamp":1707303794000},"page":"165","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["In Vitro Antibacterial Activity of Ceftobiprole and Comparator Compounds against Nation-Wide Bloodstream Isolates and Different Sequence Types of MRSA"],"prefix":"10.3390","volume":"13","author":[{"given":"Lingqin","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"},{"name":"Infectious Department, Taizhou Municipal Hospital, Taizhou 318000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangxiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunbo","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-5904","authenticated-orcid":false,"given":"Yonghong","family":"Xiao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","unstructured":"(2022, February 11). Centers for Disease Control and Prevention: Sepsis, Available online: https:\/\/www.cdc.gov\/sepsis\/what-is-sepsis.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.2147\/IDR.S412669","article-title":"Microbiological Analysis and Mortality Risk Factors in Patients with Polymicrobial Bloodstream Infections","volume":"16","author":"Xu","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_3","unstructured":"GBD 2019 Antimicrobial Resistance Collaborators (2022). Global mortality associated with 33 bacterial pathogens in 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 400, 2221\u20132248."},{"key":"ref_4","unstructured":"WHO (2020). Global Report on the Epidemiology and Burden of Sepsis: Current Evidence, Identifying Gaps and Future Directions, World Health Organization. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/334216."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/CCM.0000000000005870","article-title":"Epidemiology, Resistance Profiles, and Outcomes of Bloodstream Infections in Community-Onset Sepsis in the United States","volume":"51","author":"Ohnuma","year":"2023","journal-title":"Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jac\/dkq397","article-title":"Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: The CLASS study","volume":"66","author":"Rossolini","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e01566-18","DOI":"10.1128\/AAC.01566-18","article-title":"Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016","volume":"63","author":"Pfaller","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Duncan, L.R., Hamed, K.A., Smart, J.I., Pfaller, M.A., Flamm, R.K., and Mendes, R.E. (2022). Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020. Diagn. Microbiol. Infect. Dis., 103.","DOI":"10.1016\/j.diagmicrobio.2022.115713"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1128\/AAC.01787-10","article-title":"In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jgar.2022.05.001","article-title":"Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories","volume":"29","author":"Hawser","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dandan, Y., Shi, W., Yang, Y., Yonggui, Z., Zhu, D., Yan, G., and Hu, F. (2022). Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016\u20132018). BMC Microbiol., 22.","DOI":"10.1186\/s12866-022-02699-4"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00336-08","article-title":"In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections","volume":"52","author":"Amsler","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1151.e1","DOI":"10.1016\/j.cmi.2022.03.009","article-title":"Staphylococcal cassette chromosome mec amplification as a mechanism for ceftobiprole resistance in clinical methicillin-resistant Staphylococcus aureus isolates","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, S., Sun, S., Yang, C., Chen, H., Yin, Y., Li, H., Zhao, C., and Wang, H. (2018). The Changing Pattern of Population Structure of Staphylococcus aureus from Bacteremia in China from 2013 to 2016: ST239-030-MRSA Replaced by ST59-t437. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00332"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3201\/eid2211.160587","article-title":"Increased Community-Associated Infections Caused by Panton-Valentine Leukocidin-Negative MRSA, Shanghai, 2005-2014","volume":"22","author":"Li","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/jac\/dkz371","article-title":"Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: Activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates","volume":"74","author":"Antonelli","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hawser, S., Kothari, N., Karlowsky, J.A., Wiktorowicz, T., and Hamed, K. (2020). In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates. Diagn. Microbiol. Infect. Dis., 96.","DOI":"10.1016\/j.diagmicrobio.2019.114978"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","article-title":"Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/AAC.01403-07","article-title":"In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus","volume":"52","author":"Banerjee","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: A review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2021.07.012","article-title":"Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories","volume":"26","author":"Hawser","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10096-022-04437-0","article-title":"Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018\u20132020)","volume":"41","author":"Sader","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13756-022-01055-5","article-title":"Blood bacterial resistant investigation collaborative system (BRICS) report: A national surveillance in China from 2014 to 2019","volume":"11","author":"Chen","year":"2022","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1093\/ofid\/ofy344","article-title":"Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18574","DOI":"10.1074\/jbc.RA118.006052","article-title":"The structures of penicillin-binding protein 4 (PBP4) and PBP5 from Enterococci provide structural insights into \u03b2-lactam resistance","volume":"293","author":"Moon","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lazzaro, L.M., Cassisi, M., Stefani, S., and Campanile, F. (2022). Impact of PBP4 Alterations on \u03b2-Lactam Resistance and Ceftobiprole Non-Susceptibility Among Enterococcus faecalis Clinical Isolates. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.816657"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1128\/AAC.00983-09","article-title":"Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium","volume":"54","author":"Henry","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.cmi.2021.04.025","article-title":"Distribution of pathogens and antimicrobial resistance in bacteraemia according to hospitalization duration: A nationwide surveillance study in Switzerland","volume":"27","author":"Buetti","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jac\/dkq011","article-title":"In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals","volume":"65","author":"Silva","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.45.3.825-836.2001","article-title":"In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci","volume":"45","author":"Hebeisen","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2174\/1381612805666230112191507","article-title":"Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae","volume":"5","author":"Hanson","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1128\/AAC.00218-07","article-title":"Interactions of ceftobiprole with beta-lactamases from molecular classes A to D","volume":"51","author":"Queenan","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1086\/514909","article-title":"Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria","volume":"27","author":"Hancock","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jmii.2014.12.008","article-title":"Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)","volume":"49","author":"Jean","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1128\/AAC.00060-10","article-title":"Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole","volume":"54","author":"Queenan","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1086\/491713","article-title":"Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy","volume":"42","author":"Sakoulas","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","unstructured":"Wayne, P.A., and Clinical and Laboratory Standards Insitute (2021). M100 Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [31st ed.]."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e01663-18","DOI":"10.1128\/AAC.01663-18","article-title":"High Rate of Ceftobiprole Resistance among Clinical Methicillin-Resistant Staphylococcus aureus Isolates from a Hospital in Central Italy","volume":"62","author":"Morroni","year":"2018","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/2\/165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:38Z","timestamp":1760104598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/2\/165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["antibiotics13020165"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13020165","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}